Pliant Therapeutics Approves Key Proposals at Annual Meeting

Pliant Therapeutics ( (PLRX) ) has issued an announcement.

On April 9, 2025, Pliant Therapeutics held its Annual Meeting where stockholders voted on several key proposals. The election of John Curnutte, M.D., Ph.D., Katharine Knobil, M.D., and Thomas McCourt as Class II directors was approved, ensuring their positions until the 2028 Annual Meeting. Additionally, stockholders approved the compensation of the company’s named executive officers, an amendment to limit the liability of certain officers as permitted by Delaware law, and the ratification of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (PLRX) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Pliant Therapeutics stock, see the PLRX Stock Forecast page.

Spark’s Take on PLRX Stock

According to Spark, TipRanks’ AI Analyst, PLRX is a Underperform.

Pliant Therapeutics is currently facing substantial financial difficulties, with zero revenue in 2024 and ongoing net losses. These challenges are reflected in the low financial performance score. Technical analysis shows bearish trends but hints at a potential short-term rebound. Valuation remains poor due to a negative P/E ratio and lack of dividends. Additionally, a significant workforce reduction indicates further strategic challenges. Overall, these factors contribute to a low stock score, indicating high risk and limited appeal for potential investors.

To see Spark’s full report on PLRX stock, click here.

More about Pliant Therapeutics

Average Trading Volume: 1,257,360

Technical Sentiment Signal: Sell

Current Market Cap: $100.1M

Find detailed analytics on PLRX stock on TipRanks’ Stock Analysis page.